Myriad Genetics to Present Results from Four Studies at the American Urological Association 2017 Annual Meeting
May 05 2017 - 7:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, today announced that it will
present results from four separate prostate cancer studies at the
American Urological Association (AUA) 2017 Annual Meeting being
held May 12-16, 2017 in Boston, Mass.
“Myriad Genetics is the global leader in genetic testing for men
diagnosed with prostate cancer, and we are looking forward to
presenting four new studies at AUA this year,” said Michael Brawer,
M.D., senior vice president of Medical Affairs, Myriad Genetic
Laboratories. “We are particularly excited to present our
second validation study demonstrating the ability of the Prolaris
test to predict the 10-year risk of metastases following surgery or
radiation therapy, which should help clinicians achieve better
outcomes for their patients.”
A list of Myriad presentations at AUA 2017 is below.
Follow Myriad on Twitter via @MyriadGenetics and stay
informed about symposium news and updates by using the hashtag
#AUA17.
Poster Presentations
- Title: Evaluating the Prognostic Utility of
the CCP Score for Predicting Prostate Cancer Aggressiveness in
African American MenPresenter: Steven Bardot,
M.D., Ochsner Medical CenterDate: Saturday, May
13, 2017: 7:00-9:00 a.m. EST.Location: Room
253AB.
- Title: Prognostic Utility of Biopsy-Derived
Cell Cycle Progression Score in Patients with NCCN Low-Risk
Prostate Cancer Undergoing Radical Prostatectomy: Implications for
TreatmentPresenter: Meera Chappidi, M.P.H., M.D.
Candidate, The Johns Hopkins University School of
MedicineDate: Saturday, May 13, 2017: 7:00-9:00
a.m. EST.Location: Room 253AM.
- Title: The Impact of Clinical CCP Testing in
Men with Localized Prostate Cancer for Expanding the Population of
Men Eligible for Active SurveillancePresenter:
Behfar Ehdaie, M.D., Memorial Sloan Kettering Cancer
CenterDate: Saturday, May 13, 2017: 1:00-3:00 p.m.
EST.Location: Room 205BC.
- Title: Patient NCCN Risk Classification Based
on Combined Clinical Cell Cycle Risk (CCR)
ScorePresenter: David Crawford, M.D., University
of Colorado School of MedicineDate: Tuesday, May
16, 2017: 7:00-9:00 a.m. EST.Location: Room
161.
About Prolaris®Prolaris is a novel 46-gene
RNA-expression test that directly measures tumor cell growth
characteristics for stratifying the risk of disease-specific
mortality in patients with prostate cancer. Prolaris provides a
quantitative measure of the RNA expression levels of genes involved
in the progression of tumor growth. Low gene expression is
associated with a low risk of disease-specific mortality in men who
may be candidates for active surveillance and high gene expression
is associated with a higher risk of disease-specific mortality in
patients who may benefit from additional therapy. For more
information visit: www.prolaris.com.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
three strategic imperatives: transitioning and expanding its
hereditary cancer testing markets, diversifying its product
portfolio through the introduction of new products and increasing
the revenue contribution from international markets. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are
trademarks or registered trademarks of Myriad Genetics, Inc. or its
wholly owned subsidiaries in the United States and foreign
countries. MYGN-F, MYGN-G.
Safe Harbor
Statement This
press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to Prolaris data being presented at
the at the American Urological Association’s 2017 Annual Meeting
being held May 12-16, 2017 in Boston, Mass.; and the Company's
strategic directives under the caption "About Myriad
Genetics." These "forward-looking statements" are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those described or
implied in the forward-looking statements. These risks include, but
are not limited to: the risk that sales and profit margins of our
existing molecular diagnostic tests and pharmaceutical and clinical
services may decline or will not continue to increase at historical
rates; risks related to our ability to transition from our existing
product portfolio to our new tests; risks related to changes in the
governmental or private insurers' reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services tests and any future tests are terminated or
cannot be maintained on satisfactory terms; risks related to delays
or other problems with operating our laboratory testing facilities;
risks related to public concern over our genetic testing in general
or our tests in particular; risks related to regulatory
requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or
healthcare payment systems; risks related to our ability to obtain
new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire, including but not limited to our acquisition of Assurex,
Sividon and the Clinic; risks related to our projections about the
potential market opportunity for our products; the risk that we or
our licensors may be unable to protect or that third parties will
infringe the proprietary technologies underlying our tests; the
risk of patent-infringement claims or challenges to the validity of
our patents; risks related to changes in intellectual property laws
covering our molecular diagnostic tests and pharmaceutical and
clinical services and patents or enforcement in the United States
and foreign countries, such as the Supreme Court decision in the
lawsuit brought against us by the Association for Molecular
Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our Annual report on Form 10-K for the fiscal year ended
June 30, 2016, which has been filed with the Securities and
Exchange Commission, as well as any updates to those risk factors
filed from time to time in our Quarterly Reports on Form 10-Q or
Current Reports on Form 8-K.
Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024